GlassScriptPhysician profile
Christopher Russell
NPI 1174194351
$1,908.47
in general payments reported to CMS, 2019-2025
25 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.51 · 2024: $438 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $378.84 | 2024-2025 | Kisunla, Jardiance, Mounjaro |
| Abbvie INC. | $296.82 | 2024-2025 | |
| Pfizer INC. | $251.60 | 2024-2025 | |
| Dexcom, INC. | $119.72 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $110.77 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $95.06 | 2024-2025 | |
| Novo Nordisk INC | $94.94 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $92.71 | 2024-2025 | Airsupra |
| Boston Scientific Corporation | $84.63 | 2024-2025 | Watchman Access System |
| Exact Sciences Corporation | $46.97 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $46.76 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.15 | 2024-2025 | Jardiance |
| Insulet Corporation | $30.93 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $30.85 | 2024-2025 | Voquezna |
| Organon LLC | $24.51 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.05 | 2025 | |
| Madrigal Pharmaceuticals | $18.95 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $17.48 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $16.86 | 2025 | Nexletol |
| Aimmune Therapeutics, INC. | $14.98 | 2025 | Zenpep |
| Almatica Pharma LLC | $14.87 | 2025 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $14.70 | 2024 | |
| Amgen INC. | $14.46 | 2025 | Evenity |
| Lundbeck LLC | $14.04 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $13.82 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.